eligibility_summary
Adults (≥18) with pathologically confirmed extensive-stage SCLC (VALG), who provide informed consent, received first-line PD-(L)1 as the most recent regimen and either had no imaging response or progressed after an initial response, and have ≥1 measurable lesion per RECIST 1.1. No exclusion criteria.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial type: prospective real-world observational, no change to standard care. Population: extensive-stage SCLC patients in China who failed or did not respond to prior PD-(L)1 therapy. Interventions assessed: IBI-322 + lenvatinib. IBI-322: bispecific monoclonal antibody immunotherapy that blocks PD-L1 and CD47, aiming to restore T-cell activity (via PD-1/PD-L1 checkpoint inhibition) and enhance macrophage-mediated phagocytosis (by disrupting CD47–SIRPα “don’t-eat-me” signaling). Lenvatinib: oral multi-kinase inhibitor (VEGFR1-3, FGFR1-4, PDGFRα, RET, KIT) that suppresses angiogenesis and tumor growth. Targeted cells/pathways: PD-L1+ tumor/immune cells, CD47 on tumor cells leading to macrophage activation, T-cell checkpoint pathway, endothelial/angiogenic pathways via VEGF/FGF, additional signaling via PDGFR/RET/KIT. Biomarker assessment planned.